CONDITION

Mast Cell Tumours in Dogs

Why this matters now

Mast cell tumours are the most common malignant skin tumours in dogs, accounting for approximately 16-21% of all cutaneous neoplasms. They arise from mast cells — immune cells that normally reside in tissues throughout the body and play roles in allergic and inflammatory responses. Certain breeds carry significantly elevated risk, including Boxers, Boston Terriers, Labrador Retrievers, Golden Retrievers, Pugs, Staffordshire Bull Terriers, and Weimaraners, though the tumour can develop in any breed. Mast cell tumours present most commonly in middle-aged to older dogs, typically between 7 and 9 years of age, though they can occur in younger animals. Their behaviour ranges enormously — from benign, slow-growing masses that are cured by simple surgical removal to highly aggressive tumours with widespread metastatic potential — making accurate characterisation of each individual tumour critically important for determining the appropriate management approach.

The biological behaviour of mast cell tumours is notoriously variable and somewhat unpredictable. Low-grade tumours may remain small and localised for extended periods, growing slowly and posing minimal threat to the dog's overall health. High-grade tumours can grow rapidly, invade deeply into surrounding tissues, and spread (metastasise) to regional lymph nodes, spleen, liver, bone marrow, and other sites. The grading system — whether the traditional Patnaik three-tier system or the newer Kiupel two-tier system — provides a framework for predicting likely behaviour, but individual tumours can deviate from their predicted course. A distinctive feature of mast cell tumours is their ability to cause local and systemic effects through the release of histamine and other bioactive substances stored within the mast cell granules. This degranulation can cause local swelling, redness, and irritation around the tumour, and in some cases systemic effects including gastrointestinal ulceration, bleeding disorders, and anaphylactic-type reactions.

Signals & patterns

Early signals

A new skin lump or bump

The most common initial presentation is a single skin mass, which may appear anywhere on the body but is most frequently found on the trunk, limbs, and perineal region. Mast cell tumours are often described as the 'great pretenders' because they can mimic the appearance of virtually any other skin mass — they may be firm or soft, raised or flat, hairless or hair-covered, smooth or ulcerated. There is no characteristic appearance that reliably distinguishes a mast cell tumour from a benign lipoma, cyst, or other skin mass on visual inspection alone.

A lump that changes size

A distinctive feature of some mast cell tumours is size fluctuation. The mass may swell and shrink over days or weeks, sometimes appearing to resolve partially before enlarging again. This waxing and waning is caused by degranulation — the release of histamine and other inflammatory mediators from the tumour cells — which triggers local swelling and inflammation that can obscure or exaggerate the true tumour size. Manipulation of the mass may trigger a flare of swelling (Darier's sign).

Redness or irritation around a skin mass

The area surrounding a mast cell tumour may appear red, swollen, or irritated, sometimes with small raised wheals (urticaria) in the surrounding skin. This local inflammatory response results from histamine release from the tumour cells and can occur spontaneously or following touching, scratching, or manipulation of the mass. The dog may also lick, scratch, or pay particular attention to the area.

Multiple skin masses

While many dogs present with a single mast cell tumour, some develop multiple tumours either simultaneously or sequentially over time. Having multiple mast cell tumours does not necessarily indicate metastasis — they may represent independent primary tumours developing in a dog that is constitutionally predisposed. However, the presence of multiple masses does warrant careful evaluation of each one, as they may vary in biological grade and behaviour.

Later signals

Gastrointestinal signs

Systemic histamine release from mast cell tumours can stimulate excessive gastric acid production, leading to gastric and duodenal ulceration. Affected dogs may show vomiting (which may contain blood or coffee-ground material), dark tarry stools (melaena), reduced appetite, and abdominal discomfort. These gastrointestinal complications can occur with tumours of any location and represent a systemic effect of the tumour rather than a local phenomenon.

Enlarged regional lymph nodes

Lymph nodes draining the area containing the tumour may become enlarged, which can sometimes be detected by palpation. Lymph node involvement represents regional spread of the tumour and is an important factor in staging and prognosis. The lymph nodes most commonly affected depend on the tumour location — inguinal nodes for hind limb tumours, axillary nodes for forelimb tumours, and so forth.

General malaise and systemic illness

Dogs with advanced or high-grade mast cell tumours may develop systemic signs including lethargy, weight loss, reduced appetite, and general malaise. In severe cases, massive histamine release can produce hypotension, anaphylactic-type reactions, and coagulopathies (bleeding disorders). These systemic effects reflect the widespread impact of the bioactive substances released by the tumour cells on multiple organ systems.

Click to read about the biological mechanisms

How this is usually investigated

The investigation of a suspected mast cell tumour follows a stepwise process from initial sampling through histopathological grading and staging, with each step providing progressively more detailed information about the tumour's nature, grade, and extent of spread.

Fine needle aspirate (FNA) and cytology

Purpose: A fine needle aspirate is typically the first diagnostic step. A small needle is inserted into the mass and cells are collected for examination under the microscope. Mast cells have a distinctive appearance on cytology — their granules stain with specific dyes, making them relatively straightforward to identify. FNA can often confirm that a mass is a mast cell tumour, guiding the decision about whether and how to proceed with removal.
Considerations: While FNA is excellent for identifying the tumour type, it cannot reliably determine the histological grade, which is a critical factor in predicting behaviour and guiding management. Some mast cell tumours, particularly poorly differentiated ones, may be more difficult to identify on cytology. The sampling process itself can occasionally trigger local degranulation, causing temporary swelling around the mass.

Surgical excision and histopathology

Purpose: Surgical removal with appropriate margins followed by histopathological examination of the entire tumour provides the definitive grade, margin assessment, and detailed characterisation of the tumour's biological features. The pathologist evaluates the degree of cellular differentiation, mitotic rate, invasiveness, and completeness of surgical margins. This information is essential for predicting behaviour and determining whether additional treatment is warranted.
Considerations: The surgical approach for mast cell tumours requires planning, as achieving adequate margins (typically 2-3 cm laterally and one fascial plane deep for initial excision) is important for minimising the risk of local recurrence. The location and size of the tumour influence the feasibility of wide excision. Histopathological processing and reporting typically take several days to two weeks, during which the results are awaited before decisions about further treatment are finalised.

Regional lymph node assessment

Purpose: Evaluation of the regional lymph nodes draining the tumour site is an important component of staging. This may involve palpation, fine needle aspiration of accessible lymph nodes, or sentinel lymph node mapping. Lymph node involvement significantly affects prognosis and management recommendations, as it indicates regional spread beyond the primary tumour site.
Considerations: Even lymph nodes that feel normal in size may harbour microscopic metastatic disease, and aspiration of regional nodes is increasingly considered a standard part of mast cell tumour staging regardless of node size. The interpretation of lymph node aspirates for mast cell metastasis requires experience, as small numbers of mast cells can be present in normal lymph nodes.

Staging investigations (abdominal ultrasound, bloodwork)

Purpose: For tumours that are higher grade, large, or have lymph node involvement, further staging may include abdominal ultrasound to evaluate the spleen, liver, and abdominal lymph nodes; complete blood count to check for circulating mast cells or cytopenias; and buffy coat analysis. These investigations assess whether the disease has spread beyond the regional lymph nodes to distant sites.
Considerations: The extent of staging is typically guided by the grade and clinical presentation. Low-grade, completely excised tumours may not require extensive staging, while high-grade tumours or those with known lymph node involvement generally warrant thorough systemic evaluation. The staging results directly inform decisions about whether adjunctive treatment such as chemotherapy or radiation therapy is warranted.

Molecular testing (c-kit mutation analysis)

Purpose: Testing for mutations in the c-kit gene provides information about the tumour's molecular biology that has implications for both prognosis and potential responsiveness to tyrosine kinase inhibitor therapy. Tumours with certain KIT mutations may respond to targeted drugs that specifically inhibit the mutated receptor, offering a treatment option that is more targeted than conventional chemotherapy.
Considerations: c-kit testing is not performed on all mast cell tumours but may be particularly valuable for intermediate or high-grade tumours where targeted therapy is being considered. The test is performed on tumour tissue and requires adequate sample quality. The results are interpreted alongside the histological grade and clinical staging to develop a comprehensive management plan.

Options & trade-offs

The management of mast cell tumours is highly individualised, guided by the tumour's grade, stage, location, and the overall health and circumstances of the dog. Approaches range from curative-intent surgery for localised, low-grade tumours to multimodal protocols combining surgery, radiation, and systemic therapy for higher-grade or advanced disease.

Surgical excision alone

For low-grade mast cell tumours that can be excised with adequate margins, surgery alone is often curative. The goal is to remove the tumour with a sufficient margin of normal tissue to ensure no tumour cells remain at the surgical site. When complete excision with clean margins is achieved for a low-grade tumour, the prognosis is generally excellent, with low rates of local recurrence or distant spread.

Trade-offs: The feasibility of wide excision depends on the tumour's location, size, and the availability of tissue for closure. Some locations — particularly distal limbs, face, and perianal region — may limit the achievable margins. If margins are incomplete (tumour cells extend to the cut edge), the options include revision surgery, radiation therapy, or monitoring, depending on the grade and clinical context.

Surgery with adjunctive radiation therapy

When surgical margins are incomplete or narrow, particularly for intermediate-grade tumours, radiation therapy directed at the surgical site can reduce the risk of local recurrence. Radiation can also be used as the primary local treatment for tumours that cannot be surgically removed with adequate margins due to their location.

Trade-offs: Radiation therapy requires multiple treatment sessions delivered under general anaesthesia over several weeks, involves travel to a radiation facility (which may not be locally available), and can produce local side effects including skin changes and delayed healing. The decision to pursue radiation weighs the risk of recurrence without treatment against the practical, financial, and quality-of-life implications of the treatment course.

Systemic therapy (chemotherapy or tyrosine kinase inhibitors)

For high-grade tumours, those with lymph node or distant metastasis, or those considered at high risk of spread, systemic therapy may be recommended. Conventional chemotherapy protocols (often vinblastine-based) and targeted tyrosine kinase inhibitors (such as toceranib or masitinib) represent different approaches to controlling systemic disease. Tyrosine kinase inhibitors are particularly relevant for tumours harbouring specific c-kit mutations, where they can target the abnormal signalling pathway driving tumour growth.

Trade-offs: Systemic therapy involves ongoing treatment with associated monitoring requirements and potential side effects. Chemotherapy side effects in dogs are generally less severe than those experienced by humans but can include gastrointestinal effects and bone marrow suppression. Tyrosine kinase inhibitors can cause gastrointestinal effects, muscle pain, and protein loss through the kidneys. The treatment duration, monitoring frequency, and financial commitment are important considerations in the decision-making process.

Palliative management

For dogs where aggressive treatment is not appropriate — due to advanced disease, concurrent health conditions, age, or owner preference — palliative management focuses on maintaining comfort and quality of life. This may include medications to control histamine-related effects (antihistamines, gastroprotectants), anti-inflammatory drugs, pain management, and monitoring for complications. Some tumours may respond to palliative-dose radiation or low-dose chemotherapy aimed at slowing progression.

Trade-offs: Palliative management does not aim to cure the disease but can significantly improve comfort and quality of life. The approach requires ongoing monitoring to assess the animal's wellbeing and adjust the management plan as the condition evolves. Quality of life assessment becomes the primary guiding principle in palliative management decisions.

Common misconceptions

Misconception:

"All skin lumps on dogs are harmless fatty tumours (lipomas)"

Reality:

While lipomas are indeed the most common skin masses in dogs and are typically benign, not all skin lumps are lipomas. Mast cell tumours, in particular, can closely mimic the appearance of lipomas and other benign masses — they have no characteristic visual appearance that reliably distinguishes them. A mass that looks and feels like a harmless lipoma may be a mast cell tumour, which is why fine needle aspiration of new or changing skin masses is valuable for confirming the cell type before making assumptions about their nature.

Misconception:

"A small mast cell tumour is automatically a low-grade tumour"

Reality:

Tumour size does not reliably predict biological grade or behaviour in mast cell tumours. Small tumours can be high-grade and biologically aggressive, while large tumours may be low-grade and relatively indolent. The grade is determined by microscopic evaluation of the tumour cells' characteristics, including their degree of differentiation, mitotic rate, and invasive behaviour — features that cannot be assessed from the mass's external appearance or size alone.

Misconception:

"Once a mast cell tumour is removed, the dog is cured"

Reality:

Complete surgical removal of a low-grade mast cell tumour with clean margins does carry an excellent prognosis, and many dogs are indeed cured by surgery alone. However, dogs that have developed one mast cell tumour have an increased likelihood of developing additional mast cell tumours at new sites in the future. Regular skin checks and prompt evaluation of any new lumps are important aspects of long-term monitoring for dogs with a history of mast cell tumours. Additionally, for incompletely excised or higher-grade tumours, additional treatment may be needed to manage residual or metastatic disease.

Performing regular skin checks — running your hands over the dog's entire body in a systematic way, feeling for new lumps, bumps, or changes in existing masses — is one of the most valuable things an owner can do for a dog that is predisposed to or has a history of skin tumours. Noting the location, size (measuring with a ruler or comparing to everyday objects), firmness, and any changes over time creates a record that can be compared at future checks. Any new mass, or any change in a known mass — including growth, change in texture, redness, or size fluctuation — warrants evaluation. Fine needle aspiration is a quick, minimally invasive procedure that can typically be performed during a routine visit and provides valuable information about the cell type within a mass, helping to distinguish between benign and potentially significant lumps without the need for immediate surgical removal.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS